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IN T R O D U C TIO N
Medical students, little more than a quarter of a century ago, observed first hand the inevitable progression and early demise that characterised acute leukaemia, whether this occurred in children or adults. In contrast, there were occasional patients with a chronic variant that advanced more slowly and was com patible with extended survival albeit despite a steadily deteriorating quality of life. Since that time progress in management has been both impressive and far reaching, first with the introduction of effective chem otherapeutic agents that made disease control possible and more recently with evidence that cure is now a realistic goal for treatm ent, at least in a substantial num ber of patients. Consequently physicians, and particularly haematologists, must ensure that the available rsources are correctly allocated so that the maximum num ber of individuals, whether they be adults or children, benefit from the new knowledge accrued during the last decade.
The ever widening acceptance of the need to review older practices raises ethical questions. Should limited resources be expended on people with malignant disease? Is the treatm ent worse than the cure? Are the results of more aggressive therapy program m es sufficiently good to justify their continuation? Do multidisciplinary and specialised centres infringe in any way upon the role of the private or general physician? Is it possible to justify a w atch-and-wait approach, even in selected groups?
Conversely, and seldom debated with the same enthusiasm , is the issue of exposing a patient with chronic leukaemia to single agent therapy which is, at best, palliative and could be leukaemogenic. Such a choice may be correct but that decision requires a degree of experience seldom found when only small num bers of patients are treated. Similarly, and of even greater concern, is the not infrequent practice of failing to provide reliable inform ation about the alternative treatm ent options, at least one of which is potentially curative.
To place in perspective some of these relevant issues the clinical presentation for each disease will be outlined and followed by a brief summ ary of diagnostic methods, emphasising areas where new inform ation is available. Conventional management will then be contrasted with currently preferred therapy emphasising the need for recognising and stratifying patients to appropriate options according to prognostic factors. Where it is relevant prevailing controversy will be commented on in an attem pt to provide a perspective for prim ary care physicians and paramedical professionals in advising their patients about treatm ent.
Finally, the argum ent will be advanced that, with improved understanding in the biology and treatm ent of these diseases, it is advisable for patients to be referred to specialist haematologists in preference to the older practice of single agent adm inistration by general practitioners or physicians.
C H R O N IC GRA N ULO CY TIC LEUK A EM IA
The clinical presentation is variable since the disease may be found in childhood but has an incidence between 30-40 years in Blacks, 40-60 years in those of mixed ancestry and 50-70 years in Whites (1). In the post-pubertal patient the first abnorm ality detected may be on a routine blood count where an absolute and left shifted granulocytosis is uncovered. More usually a mild degree of anaem ia may give rise to symptoms while a dragging sensation in the back or left upper quadrant discom fort may draw attention to a spleen which is frequently moderately and occasionally massively enlarged (1). The rem ainder of the physical exam ination is usually negative although in advanced disease cachexia occurs. We have been unable to confirm reports about prom inent lym phadenopathy in black patients (2) .
The clinical course typically has three stages. The first, which is designated the stable phase, has a median duration of about 36 m onths and symptoms are easy to control with therapy. In the second, defined as acceleration, the blood count may not change markedly but there is deterioration in perform ance status, weight loss, sweating, increasing organ enlargement and the need for larger quantities of chemotherapy. The third phase is blastic transform ation and here it is essential to recognise that the acute leukaemia may be lymphoblastic in 25% of cases with im portant implications for ^ management. D iagnosis rests primarily on finding a raised white count in which the differential distribution usually has two peaks with one in m ature neutrophils and a second in the myelocytes: occasional blast cells will frequently be circulating. In the bone marrow there is massive granulocytic hyperplasia with loss of fat spaces, increase in reticulin and megakaryocytic hyperplasia with striking morphologic abnormalities.
Chrom osom al studies will typically show the balanced reciprocal translocation of material between the long arms of chromosom e 9 and 22 (3) and no patient should have this diagnosis accepted without supportive cytogenetic data. The current evidence would suggest that the Philadelphia-negative variant is more properly considered am ong the myelodysplastic syndromes and then specifically classified as chronic m yelomonocytic leukaemia. Biochemical profile is not particularly helpful other than dem onstrating a raised urate level and thereby emphasising the im portance of adm inistering the xanthineoxidase inhibitor, allopurinol, before commencing chemotherapy.
Where cytogenetic studies are not readily available the low levels or absence of leukocyte alkaline phosphatase in granulocytes is helpful. Of interest, but not essential to the haematologic diagnosis, are studies correlating changes in the distribution of plasminogen activator secreted by the leukaemic blasts in culture (4) where preliminary studies suggest that prominence of the tissue species of enzyme over its urokinase form predicts for disease acceleration and blastic transform ation.
Conventional m anagem ent was, for a long time, oral myleran. Starting dose with this agent vary with the white cell count but are usually in the range of 4-6 mg and are then titrated to keep the total granulocyte count around 10 X 109/L at which time the patient should have an impalpable spleen. The dangers of myleran have long been recognised and recent studies have re-emphasised these (5): accordingly hydroxyurea is currently the preferred agent. With the latter drug it should be appreciated that a marked increase in mean cell volume is a characteristic finding and does not constitute an indication for measurement or adm inistration of folate or vitamin BI2.
It is during this chronic stable phase that m anagem ent is easy with either drug adm inistration or radiotherapy (6) so that both general practitioners and physicians have felt justified in holding on to their patients. This is a critical phase in determining survival and it is therefore unfortunate that these individuals are not clearly informed th at they are receiving palliative management. Conversely other options, that include bone marrow transplantation in suitably selected patients and which offer a chance for cure although associated with greater degrees of m orbidity and m ortality, are often never even discussed.
D uring the accelerated or blastic phase ^B h e outlook is poor and there is an ^u n d e rs ta n d a b le degree of nihilism even in centres that have developed expertise in this area. A particular problem is rapid splenic enlargement frequently associated with exquisite pain as a result of multiple infarctions. Prior splenectomy is the only way to avoid this com plication but the routine use of this operation remains controversial. M anagement for patients during this short term inal period, which seldom extends beyond 3 months, is limited to analgesia although on occasions sym ptom atic relief can be achieved with the oral cytotoxic drug com bination of etoposide and an anthracyline antibiotic. The preferred management is immediate referral to a centre having an established protocol for the investigation and accurate characterisation of the disease. The initial treatm ent is adm inistration of hydroxyurea to return the expanded granulocyte mass to w a r d s normal. Based on a retrospective ^B u d y (Jacobs, W ood and Dentunpublished) splenectomy is reserved for selected patients rather than, as previously employed, on a routine basis. In those patients under 45 years with a suitable donor allogeneic bone marrow transplantation is the recommended form of treatm ent (7). There are subtleties to this procedure that include differences in the preparative or conditioning regimens that may be ablative radiotherapy, chem otherapy or com binations of the two. Furtherm ore ex vivo m anipulation of the graft may be undertaken since T-cell depletion will reduce the incidence and severity of acute and chronic graft-versushost disease (GvHD) but there are suggestions that this m anipulation may be associated with a higher leukaemic relapse rate. Alternatively whole marrow may be infused and post-transplantation imm unosuppressive regimens employed to modulate the expression of G vH D, particularly since this phenom enon may have some anti-leukaemic benefits: a currently favoured regimen is the com bination of ciclosporin and methotrexate.
Those patients who are not eligible for bone marrow transplantation, who cannot be adequately informed of the risks involved or who elect not to be grafted can be managed with biological immune response m odulation using recom binant alpha interferon (8) , with or without additional hydroxyurea. Earlier suggestions that autologous bone marrow transplantation may delay the onset of accelerated or blastic phase have not been confirmed. However studies are presently in progress to determine whether it is possible to eradicate the leukaemic clone by long-term bone marrow culture using the Dexter technique (9) and then to re infuse adequate numbers of these "purged" haem atopoietic stem cells after aggressive therapy to eradicate the leukaemic process in the patient.
During the accelerated or blastic phase allogeneic bone marrow transplantation has been shown to have a substantial response rate and a num ber of such patients, albeit considerably less than those transplanted during the stable phase, will achieve long disease-free survival and certainly some will be cured (10) .
The ethical considerations are particularly im portant since cure is now a realistic goal for therapy. Many of these patients are young and there can be no justification for not offering them the opportunity to consider marrow grafting should a suitable donor be available. The ability to understand the procedure is im portant since this more aggressive approach has a higher morbidity and m ortality in the short term than single drug palliative therapy. However since the long term results are clearly superior there can be no question that transplantation programmes should be major com mitm ents in university centres. A nother aspect of im portance is the misconception that referral of patients in this way conflicts with what is best for that individual. Exactly the opposite is true. Thus optim um treatm ent by a multidisciplinary group protects the patient from inappropriate treatm ent, balances available options carefully against prognostic factors including social circumstances and then provides the patient with a comprehensive explanation of the choices. Only under these circumstances can properly informed consent be obtained and this is a necessary step for the voluntary participation in protocol studies approved by Ethics and Research Committees. Diagnosis generally requires an elevated absolute lymphocyte count although with im m unopherotyping (11) a much greater degree of com idence is possible at counts that may remain in the norm al range having only a relative lymphocytosis present. These studies also provide a much more secure basis for the clonal nature of these disorders. It needs to be appreciated that with current sub-division of patients as a basis for therapy, exemplified by the use of interferon in those with hairy cell leukaemia, accuracy at this initial stage is of increasing im portance. Classification may be refined with cellular and molecular biologic techniques that include the dem onstration of rearranged im m unoglobulin and T-cell receptor genes. Im m unoglobulin levels in the plasm a are generally reduced and may be associated with m onoclonal spikes or secretion of light-chains in the urine.
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Bone marrow aspiration shows an increased num ber of lymphocytes whereas trephine biopsy provides valuable inform ation on staging (12). Cytogenetic studies have been less well developed in the chronic lym phoproliferative disorders than in granulocytic tum ours but nevertheless all such patients should be examined since the presence of karyotypic defects predict for more aggressive clinical course.
On the basis of laboratory data patients are staged (13, 14) and it is particularly im portant to define perform ance status (15) .
Conventional management is based on the observation that early stage disease, particularly in the elderly, is slowly progressive and often relatively stable. U nder these circumstances a watch-andwait attitude may be appropriate. More usually however patients require therapy because of an accelerating clinical tempo or the presence of extensive enlargement of lymph nodes or spleen and have traditionally received the alkalating agent chloram bucil (16) with or without prednisone: those who failed to respond needing additional drugs such as cyclophosphamide or occasionally cytosine arabinoside (17) . Low-dose total body irradiation has been dem onstrated in prospective randomised study to be without significant side effects and approxim ately equivalent to this kind of low-level palliative chem otherapy (18) .
The preferred m anagem ent is best determined by early referral to a'centre that has accum ulated a substantial experience over many years and where all the necessary diagnostic techniques are available. Only under these circumstances can patients be properly staged and benefit from rationally based therapy, whether this be expectant or definitive. The older practice of referral only once a refractory clone has emerged, haem atopoietic reserve is eroded from prior inappropriate palliative therapy and the patients are generally in poor clinical condition is to be deprecated.
In the newly diagnosed patient an essential determ inant for treatm ent is the extent or stage of the disease. The various procedures on which this depends should be carried out by a multidisciplinary group and take into account any associated medical conditions as reflected in the perform ance status as well as the socio economic circumstances. Among the other variables that receive particular attention are the rate at which the disease is progressing and the patients age. Only once all of these have been considered is it possible to offer an appropriate form of comprehensive management.
In those patients with minimal disease and in whom careful surveillance has docum ented clinical and haematologic stability there is a reasonable argum ent for observation alone: the watch-and-wait policy.
Where treatm ent is justified prospective controlled data (19) have dem onstrated the benefits of a four drug regimen containing cyclophosphamide, adriamycin, vincristine and prednisone that goes by the acronym of CH O P. Preliminary studies using high dose cyclophosphamide (Jacobsunpublished) have dem onstrated efficacy with prom pt return of the bone marrow to normal but it is yet to be determined whether such patients will requm aintenance or even th at survival is significantly prolonged. These more aggressive approaches are consistent with a similar shift in managing indolent or low grade m alignant lym phom a and m ulti-drug regimens evaluated at the N ational Cancer Institute docum ent a significant increase in complete remission rates and disease-free survival (20) .
At least three other options are available.
Firstly there is precedent for allogeneic bone marrow transplantation in a small group of selected individuals whereas autologous grafting with appropriate ex vivo purging with monoclonal antibodies is an encouraging alternative (21).
Secondly biological immune response m odulation is being actively developed. In this regard m onoclonal antibodies may be adm inistered in vivo and such serotherapy is theoretically sound but remains an experimental approach. Conversely recom binant alpha interferon is clearly established in some of the variants most notably hairy cell leukaemia (22) . It has recently been shown that this agent is also effective in the prolymphocytic sub-type (23) but it remains to be established to what extent these agents will become generally applicable to chronic lymphocytic leukaemia and at the present time there is no uniformity about the choice of agent or the schedule likely to be most effective.
Thirdly, either as initial therapy or once drug treatm ent has failed, sequential half body irradiation is clearly of benefit (24) . In this context it appears that high doses may be given with preservation of haem atopoietic reserve provided that exposure rates are low. It is clear that, here again, considerable experience is necessary to optimally use this more recently introduced form of management.
A nother area that is destined to play an im portant role in managing these patients is the availability of recom binant growth factors. Thus the granulocyte: m acrophage-colony stimulating factor or interleukin 3, which is also known as m ultipoietin, offer potent means for stim ulating marrow regeneration following the use of myelosuppressive drugs or radiotherapy. Clearly these biological products will make it possible to escalate dosage and simultaneously reduce the hazards of neutropenia and throm bocytopenia.
Splenic enlargement also requires comment. Thus where there is associated immune destruction of blood cells that have responded inadequately to corticosteroids, splenectomy is an effective means of re-establishing control over the disease. However these patients are significantly im m unocom prom ised and judgem ent as to the timing of this procedure requires a great deal of experience. Furtherm ore in certain of the variants, most notably hairy cell leukaemia, splenectomy is first step in managing the patient (25) although it is possible that interferon may circumvent this surgical procedure in some individuals. The results of ongoing clinical trials to define the respective role of these two approaches to splenomegaly will influence future practice.
The ethical considerations are noteworthy. These improving results place a direct responsibility on referral centres to ensure that investigation and staging are comprehensive and then to encourage entry into protocols designed to advance knowledge concurrently with selection of optim um treatm ent for each person. This renewed interest in lymphocytic leukaemia derives from the clear dem onstration that survival can be improved by m ulti-drug regimens. At the same time proper stratification will identify and divert from aggressive therapy that sub-population where observation or only palliative medication is more appropriate.
The role of the general practitioner or physician should not be overlooked since many of these patients are elderly and have associated ailments that can perfectly well be managed in the home circumstances. In this latter regard there needs to be a clear understanding as to the special hazards of the disease, potential com plications of superimposed chem otherapy and the particular dangers of infections that may well be trivial in the general population. The latter is exemplified by bacterial pneum onia which is often rapidly fatal in the im m unocom prom ised patient. Approached in such a balanced way the patients best interests are most likely to be served. 
Su m m a ry
CO N CLU SIO N S
In patients with the chronic leukaemias the time has come to critically review the conventional wisdom of autom atically palliating everybody who needs treatm ent with only a single drug (26) . It is true that initially most will do well but there is typically concurrent disease advancement, loss of haem atopoietic reserve and decrease in perform ance status. Unfortunately it is only at this late stage that most individuals are referred to academic centres so it is not surprising that results are then poor.
Conversely recent advances have established that cure is a realistic goal in certain young patients with chronic granulocytic leukaemia seen during the chronic stable phase. Similarly drug com binations for the chronic lymphoproliferative disorders have a significantly superior disease-free survival in com parison to more conservative approaches.
In order that each individual can be optimally evaluated, using all modern diágnostic techniques and then rational decisions made about treatm ent taking into account currently recognised prognostic factors, it would seem most responsible to arrange referral to a multidisciplinary group that have accum ulated the necessary experience over prolonged periods of time. This approach has the additional advantage that patients will be entered on properly structured trials and it is well recognised that, for any given form of treatm ent, they will do significantly better when entered into a carefully supervised protocol than com m unity treated individuals.
It is apparently also necessary to restate the fact that such programmes make allowance for all the variables that include age and social circumstance which, particularly in local practice, may become ■xclusions from randomised study, ru rth erm o re this approach does not exclude participation of the general practitioner or physician since both will continue to see their patients for minor ailments. It is also clearly necessary to appreciate the geographical constraints that exist in this country. Thus, while the recom m endation stands for referral to specialised clinics, local custom or the distances involved may complicate the delivery of optim al therapy and here there exists a place for com passionate care and the use of palliative programmes.
Undoubtedly the contem porary management of chronic leukaemia has become a much more exacting requirem ent than in the past and, all other arguments notw ithstanding, the current evidence provides a compelling reason for acknowledging that the investigation and treatm ent of these patients now falls Í learly within the am bit of haematologic |>ecialists. To ensure that all aspects of m eir care receive proper consideration a multidisciplinary approach is to be favoured. This includes a sound knowledge of cancer chem otherapy, participation by social workers and radiotherapists in a clinic that has ready access to the sophisticated practices of cell support and bone m arrow transplantation while additional responsibilities are the study and use of recom binant growth factors and biologic immune response modifiers. The future is encouraging and these directions more than justify a reasonable allocation of clinical and research resources to university hospitals that have made a com m itm ent to the systematic study and treatm ent of haematologic malignancies.
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